Evidence map›Paper›PMID 35263216›Full record

ArticleBioengineered2022

Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.

Leiming Wang, Xi Yang, Fei Zhou, Xuesi Sun, Shulin Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Dual effects of circRNA in thyroid and breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Leiming WangDepartment of General Surgery, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province 223600, China.ORCID 0000-0002-7500-8432
Xi YangDepartment of General Surgery, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province 223600, China.
Fei ZhouDepartment of General Surgery, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province 223600, China.
Xuesi SunDepartment of General Surgery, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province 223600, China.
Shulin LiDepartment of General Surgery, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian City, Jiangsu Province 223600, China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (CircRNAs) have attracted increasing attention in the diagnosis and treatment of human cancers. CircUBAP2 has been identified to promote the progression of triple-negative breast cancer (TNBC), but the function of circUBAP2 in the cisplatin (DDP) resistance of TNBC remains obscure. Our investigation showed that circUBAP2 was significantly upregulated in DDP-resistant TNBC and TNBC sensitivity to DDP could be enhanced by silencing of circUBAP2. Moreover, circUBAP2 was revealed to be a ceRNA for miR-300 to upregulate the expression of anti-silencing function 1B histone chaperone (ASF1B). The effect of circUBAP2/miR-300/ASF1B axis on DDP resistance of TNBC was evaluated by rescue experiments, which demonstrated that circUBAP2 inhibited TNBC sensitivity to DDP through miR-300/ASF1B axis. Furthermore, it was discovered that ASF1B activated PI3K/AKT/mTOR signaling to facilitate the DDP resistance of TNBC cells. In summary, this research revealed a novel regulatory mechanism that circUBAP2 functioned as ceRNA of miR-300 to upregulate ASF1B, which further triggered the PI3K/AKT/mTOR (PAM) signaling to enhance the DDP resistance of TNBC.

Indexed as

MicroRNAsTriple Negative Breast NeoplasmsCell Cycle ProteinsCell Line, TumorCell ProliferationCisplatinDrug Resistance, NeoplasmHistone ChaperonesHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, CircularTOR Serine-Threonine KinasesASF1B protein, humanCell Cycle ProteinsCisplatinHistone ChaperonesMicroRNAsMIRN300 microRNA, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, CircularTOR Serine-Threonine KinasesceRNACircUBAP2cisplatinPI3K/AKT/mTOR signalingTNBC

Identifiers

PMID35263216
PMCPMC8973968
OpenAlexW4221095464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.